Interventions Delivered in the Community Pharmacy to Manage Allergic Rhinitis- A Systematic Review of the Literature

José, Jéssica; Cvetkovski, Biljana; Kritikos, Vicky; Tan, Rachel; Bosnic‐Anticevich, Sinthia; Lourenço, Olga

doi:10.3390/pharmacy8020080

Cited by 3 publications

(5 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The features of the middle turbinate allow for more precise detection of the study population, monitoring of disease progression, and decision for medical treatment or surgical intervention. In contrast to previous similar studies, the lack of endoscopic features for disease progression and often limited patient-reported outcomes is addressed in this study [ 13 , 16 , 43 ].…”

Section: Discussionmentioning

confidence: 97%

See 1 more Smart Citation

The effectiveness of pharmacist-led educational model in adult patients with allergic rhinitis: a single-center randomized control trial protocol (AR-PRISE RCT)

Chew,

Lim,

Letchumanan

et al. 2024

Trials

View full text Add to dashboard Cite

Background Allergic rhinitis is a chronic respiratory disorder that significantly impacts patients’ quality of life (QoL) and work performance. Pharmacists are recognized as suitable professionals to provide patient education and pharmaceutical care for managing allergic rhinitis patients. However, local clinical practice guidelines, particularly regarding pharmaceutical care in public healthcare institutions, are lacking. This study protocol outlines a randomized controlled trial (RCT) designed to evaluate the effectiveness of a pharmacist-led educational model (AR-PRISE Model) in managing allergic rhinitis in adult patients compared to standard pharmaceutical care. The AR-PRISE model delivers patient educational material and a pharmaceutical care algorithm. Method This is a 6-month, single-center, prospective, randomized, two-arm, and parallel-group controlled trial. The trial recruits patients attending the otorhinolaryngology clinics of a tertiary referral hospital. Participants are randomized into control or intervention groups in a 1:1 ratio using permuted block randomization. The total number of participants estimated is 154, with each group requiring 77 participants. The control group receives standard pharmaceutical care, while the intervention group receives pharmacist-led education according to the AR-PRISE model. Both groups are assessed for middle turbinate endoscopy findings, disease severity, knowledge level, symptom control, medication adherence, and QoL at baseline and the end-of-study follow-up (day 180 ± 7). Depending on feasibility, intermediate follow-ups are conducted on days 60 ± 7 and 120 ± 7, either virtually or face-to-face. During intermediate follow-ups, participants are assessed for symptom control, medication adherence, and QoL. The intention-to-treat analysis includes all participants assigned to each group. An independent T-test compares the mean difference in knowledge level between the two groups. A two-way repeated measures ANOVA analysis is employed to determine between-group differences for scores of symptom control, adherence rate, and QoL. A P-value < 0.05 is considered statistically significant. Discussion This study protocol will provide a framework for conducting a randomized controlled trial (RCT) to evaluate the effectiveness of pharmacist-led education intervention in managing allergic rhinitis within public healthcare settings. The parameters measured in this trial will quantify outcomes associated with improvements in symptoms and QoL. By systematically assessing these outcomes, we aim to contribute valuable insights into the role of pharmacist-led interventions in enhancing the management of allergic rhinitis in public healthcare settings. Trial registration ClinicalTrials.gov NCT06027736. Registered on 9 July 2023—retrospectively registered.

show abstract

Section: Discussionmentioning

confidence: 97%

“…Only four studies were conducted between 2000 and 2020, focusing on educational interventions, mixed-method pharmacist versus patient-goal settings, and a case study observing the impact of pharmaceutical care [ 12 – 15 ]. Further research is needed to determine measurable outcomes in patients with allergic rhinitis [ 16 ].…”

Section: Introductionmentioning

confidence: 99%

The effectiveness of pharmacist-led educational model in adult patients with allergic rhinitis: a single-center randomized control trial protocol (AR-PRISE RCT)

Chew,

Lim,

Letchumanan

et al. 2024

Trials

View full text Add to dashboard Cite

show abstract

“…"Pharmaceutical services" from pharmacists who have been trained in allergic rhinitis management improve patients' symptom control and quality of life. [ 12 ].…”

Section: Role Of Pharmacistsmentioning

confidence: 99%

“…The Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines have been used by health care professionals internationally for allergic rhinitis management [ 1 , 11 ]. A lack of knowledge of ARIA among pharmacists is observed as evidenced by insufficient counselling and treatment selection by pharmacists in allergic rhinitis management [ 12 ]. In a recent study, it was found that 40.4% of Malaysian pharmacists have inadequate awareness of the ARIA guidelines [ 13 ].…”

Section: Introductionmentioning

confidence: 99%

The management of allergic rhinitis by pharmacists in public services: a proposed PhaRmacISt-led Education Model (AR-PRISE)

Chew

Chang

Lim

et al. 2022

J of Pharm Policy and Pract

View full text Add to dashboard Cite

Allergic rhinitis has been identified as a major respiratory disease that places a significant burden on patients and the healthcare system. Nevertheless, the management of allergic rhinitis is challenging for both patients and practitioners. Pharmacists have been recognised as strategic in providing advice for allergic avoidance, disease information, and pharmacological care for allergic rhinitis management. This role has been underutilised in the public health service sector in Malaysia due to variation in practice, regulation, and health system structures when compared to the international guidelines. This article proposed a PhaRmacISt-led Education Model (AR-PRISE) that includes explicit patient education materials and an algorithm for structured counselling by pharmacists in the management of patients with allergic rhinitis.

show abstract

“…Pharmacist-led educational interventions improve patients' quality of life and symptom severity [ 14 ]. Pharmacists significantly influence patients' management of AR [ 15 , 16 ] by setting goals for care and providing pharmacist-led educational interventions [ 17 , 18 ].…”

Section: Introductionmentioning

confidence: 99%

Development and validation of a pharmacist-led education model in allergic rhinitis management: a multi-phase study

Chew,

Lim,

Letchumanan

et al. 2023

J of Pharm Policy and Pract

View full text Add to dashboard Cite

Background Patient education is identified as one of the core and fundamental management strategies in the management of allergic rhinitis. The Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines developed guidance for the management of allergic respiratory disease, and the guidelines are applicable to the international context. The ARIA guidelines for the pharmacy have specifically encouraged the creation of local pharmacist-led intervention in allergic rhinitis management. This study aims to develop a pharmacist-led educational model using a multi-phase study approach. Method In phase one, we conducted a literature review using four databases to extract relevant articles and clinical practice guidelines published between 2017 and 2022. The information was structured into a questionnaire consisting of patient education material (10 domains with 130 items) and pharmacist counseling scopes (15 domains with 43 items), with each item having a rating scale ranging from 1 (lowest) to 9 (highest) level of agreement. Fifty-two panellists, including otorhinolaryngologists and pharmacists, were invited to complete the questionnaire. A consensus agreement was considered when at least 70% of panellists scored 7 to 9 (critically important). A two-round survey was conducted, and descriptive analysis, inter-rater reliability (≥ 0.5–1 indicate moderate to excellent reliability), variation in the relative interquartile (VRIR < 0.3 indicate good stability), and variation in the coefficient of variation (VCV < 40% considered consensus achieved) were performed. In phase two, patient education material was developed into audio-visual format, and in phase three, patients rated its understandability and actionability using a validated Patient Education Materials Assessment Tool. Results In the round one Delphi survey, 43 panellists responded, with 171 out of 173 items achieving “consensus agreement” (75.4–100%). In the second survey, 32 out of 43 panellists responded, with most items (171 out of 173 items) stable across rounds and all items had acceptable internal consistency (VCV: − 12.21–15.81). Two items did not achieve “consensus agreement” (64%) but improved in round two (92.9%), however, instability was observed (VRIR: 0.36). These two items were retained in the model due to achieving the minimum level of agreement and internal consistency (VCV = 15.81). Inter-rater reliability was 0.608 and 0.970 in the respective rounds. Patients rated the educational material as understandable (81.8–100%) and actionable (100%). Conclusion The validated pharmacist-led education model, with its educational materials tested on end-users, provides structured patient education and pharmaceutical care in assisting patients with allergic rhinitis. The educational material allows the delivery of standardized information by the healthcare providers to the patients. Further research on the effectiveness of this model in improving patients’ symptom control and quality of life is warranted.

show abstract

Interventions Delivered in the Community Pharmacy to Manage Allergic Rhinitis- A Systematic Review of the Literature

Cited by 3 publications

References 34 publications

The effectiveness of pharmacist-led educational model in adult patients with allergic rhinitis: a single-center randomized control trial protocol (AR-PRISE RCT)

The effectiveness of pharmacist-led educational model in adult patients with allergic rhinitis: a single-center randomized control trial protocol (AR-PRISE RCT)

The management of allergic rhinitis by pharmacists in public services: a proposed PhaRmacISt-led Education Model (AR-PRISE)

Development and validation of a pharmacist-led education model in allergic rhinitis management: a multi-phase study

Contact Info

Product

Resources

About